文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

美国俄亥俄州儿童大环内酯类耐药肺炎支原体感染

Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA.
PubMed 文献 · Emerg Infect Dis · 2021-01-01

该研究对美国俄亥俄州中部儿童肺炎支原体标本进行培养和测序,检测大环内酯类耐药突变,并比较耐药与敏感感染者的特征。结果显示耐药率低(2.8%),但耐药感染者住院时间更长、更易既往使用大环内酯类、更易换用替代抗菌药物,且儿科重症监护室入住odds约高5倍。

要点

  • 儿童肺炎支原体大环内酯类耐药率低(2.8%),但仍需警惕耐药株导致重症。
  • 耐药感染者住院时间更长,更易既往使用大环内酯类并换用替代药物。
  • 耐药感染者儿科重症监护室入住odds约增加5倍。

核心结论

  • 俄亥俄州中部儿童大环内酯类耐药肺炎支原体感染率低,但耐药株可导致更严重疾病。

研究设计与样本

  • 对PCR阳性肺炎支原体标本进行培养和测序检测大环内酯类耐药突变,并回顾病历比较耐药与敏感组特征。

主要发现

  • 共鉴定14例(2.8%)耐药和485例(97.2%)敏感样本。
  • 两组人口学和临床特征相似,但耐药组住院时间更长、更易既往使用大环内酯类、更易换用替代抗菌药物。
  • 耐药组儿科重症监护室入住odds约高5倍。

临床怎么用

  • 临床医生应意识到大环内酯类耐药肺炎支原体虽率低,但仍可能导致重症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Emergence of macrolide-resistant Mycoplasma pneumoniae (MRMp) challenges empiric macrolide therapy. Our goal was to determine MRMp rates and define characteristics of children infected with macrolide-sensitive M. pneumoniae (MSMp) versus MRMp in Ohio, USA. We cultured PCR-positive M. pneumoniae specimens and sequenced M. pneumoniae-positive cultures to detect macrolide resistance mutations. We reviewed medical records to compare characteristics of both groups. We identified 14 (2.8%) MRMp and 485 (97.2%) MSMp samples. Patients in these groups had similar demographics and clinical characteristics, but patients with MRMp had longer hospitalizations, were more likely to have received previous macrolides, and were more likely to have switched to alternative antimicrobial drugs. MRMp-infected patients also had ≈5-fold greater odds of pediatric intensive care unit admission. Rates of MRMp infections in children in central Ohio are low, but clinicians should remain aware of the risk for severe illness caused by these pathogens.

来源:Emerg Infect Dis,查看原文。版权归原作者所有。

引用

  1. Lanata MM, Wang H, Everhart K, et al. Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA. Emerg Infect Dis. 2021. PMID: 34013867. doi:10.3201/eid2706.203206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。